Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jena Krueger

Showing results (1-10 of 6) with videos related to

Pageof 1
Sort By:
Pediatric Neurology Briefs|December 30, 2020
Prognosis in Pediatric Myasthenia GravisJena Krueger
Pediatric Neurology Briefs|March 3, 2016
Incidence of Dravet Syndrome in a US PopulationJena Krueger, Anne T Berg
Advances in Therapy|February 20, 2026
Summary of Research: Risdiplam Treatment Following Onasemnogene Abeparvovec in Individuals with Spinal Muscular Atrophy: A Multicenter Case SeriesMelissa D Svoboda, Nancy Kuntz, Carmen Leon-Astudillo, et al.
BMC Neurology|July 7, 2025
Risdiplam treatment following onasemnogene abeparvovec in individuals with spinal muscular atrophy: a multicenter case seriesMelissa D Svoboda, Nancy Kuntz, Carmen Leon-Astudillo, et al.
Neurology. Clinical Practice|October 14, 2024
Spinal Muscular Atrophy Update in Best Practices: Recommendations for Treatment ConsiderationsMary K Schroth, Jennifer Deans, Diana X Bharucha Goebel, et al.
The Lancet. Neurology|August 16, 2025
Safety and efficacy of apitegromab in nonambulatory type 2 or type 3 spinal muscular atrophy (SAPPHIRE): a phase 3, double-blind, randomised, placebo-controlled trialThomas O Crawford, Laurent Servais, Eugenio Mercuri, et al.
Pageof 1

Showing results (1-10 of 6) with videos related to

Sort By:
Pageof 1
Pediatric Neurology Briefs|December 30, 2020
Prognosis in Pediatric Myasthenia GravisJena Krueger
Pediatric Neurology Briefs|March 3, 2016
Incidence of Dravet Syndrome in a US PopulationJena Krueger, Anne T Berg
Advances in Therapy|February 20, 2026
Summary of Research: Risdiplam Treatment Following Onasemnogene Abeparvovec in Individuals with Spinal Muscular Atrophy: A Multicenter Case SeriesMelissa D Svoboda, Nancy Kuntz, Carmen Leon-Astudillo, et al.
BMC Neurology|July 7, 2025
Risdiplam treatment following onasemnogene abeparvovec in individuals with spinal muscular atrophy: a multicenter case seriesMelissa D Svoboda, Nancy Kuntz, Carmen Leon-Astudillo, et al.
Neurology. Clinical Practice|October 14, 2024
Spinal Muscular Atrophy Update in Best Practices: Recommendations for Treatment ConsiderationsMary K Schroth, Jennifer Deans, Diana X Bharucha Goebel, et al.
The Lancet. Neurology|August 16, 2025
Safety and efficacy of apitegromab in nonambulatory type 2 or type 3 spinal muscular atrophy (SAPPHIRE): a phase 3, double-blind, randomised, placebo-controlled trialThomas O Crawford, Laurent Servais, Eugenio Mercuri, et al.
Pageof 1